Trader Alert: Unusual Volume Spotted in Cymabay Therapeutics, Inc. (NASDAQ:CBAY)

Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25. The stock increased 8.49% or $1.04 during the last trading session, reaching $13.29.

Cymabay Therapeutics (NASDAQ:CBAY) shares traded on 10.2% above secure line and closed at $13.5. It has outperformed by 52.56% the S&P500. The stock holds an average trading capacity of 719.11K shares for the past three months. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company's stock valued at $20,588,000 after acquiring an additional 376,745 shares during the last quarter. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87. Volume is simply the number of shares or contracts that trade over a given period of time, usually a day. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has risen 82.02% since February 13, 2017 and is uptrending. Republic Services had 40 analyst reports since August 19, 2015 according to SRatingsIntel. (NASDAQ:CBAY) hit a new 52-week high and has $15.08 target or 3.00% above today's $14.64 share price. (NYSE:ETM) has "Equal-Weight" rating given on Friday, December 11 by Stephens. 6,329 shares valued at $420,883 were sold by Hughes Jeffrey A on Tuesday, September 12. BTIG Research maintained the stock with "Hold" rating in Tuesday, August 22 report. KeyBanc Capital Markets maintained Republic Services, Inc. The rating was downgraded by H.C. Wainwright to "Neutral" on Wednesday, June 1. The stock has "Hold" rating by RBC Capital Markets on Tuesday, May 30.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.14, from 0.98 in 2017Q2. It turned negative, as 55 investors sold ABBV shares while 640 reduced holdings. Wells Fargo & Company MN raised its stake in Flexion Therapeutics by 1,024.1% in the fourth quarter. Eastern Bank sold 22,624 shares as Salesforce.Com (CRM)'s stock rose 7.28%. Credit Suisse Ag accumulated 134,391 shares. M&T Bancshares holds 0.01% or 17,758 shares. California Pub Employees Retirement Sys holds 17,600 shares or 0% of its portfolio. Cetera Advsrs Limited Liability Co stated it has 0.01% in Republic Services, Inc. It also reduced its holding in Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) by 97,000 shares in the quarter, leaving it with 258,667 shares, and cut its stake in Bluebird Bio Inc (NASDAQ:BLUE). Employees Retirement System Of Texas has 181,700 shares for 0.16% of their portfolio. Moreover, Heartland Advsrs has 0.75% invested in Accuray Incorporated (NASDAQ:ARAY) for 2.91M shares. The number of shares now owned by investors are 93.32 mln. (NYSE:RSG) shares with value of $1.49M were sold by SLAGER DONALD W.

Flexion Therapeutics, Inc. (FLXN) has the market capitalization of $896.29 Million. The company has market cap of $736.89 million. It engages in developing seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The simple logic that a stock's current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run is behind shareholders' inclination toward low P/E stocks. The companyÂ's product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Читайте также: Uzbek man pleads guilty in Stockholm terror trial

Analysts at Evercore ISI Group has started coverage for shares of CymaBay Therapeutics (NASDAQ:CBAY) in a research report sent to clients and investors on 13 February.

Cymabay Therapeutics, Inc. (CBAY) has an Analysts' Mean Recommendation of 1.7.

Consequently Cymabay Therapeutics (NASDAQ:CBAY)'s weekly and monthly volatility is 9.13%, 7.25% respectively. After $-0.21 actual EPS reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10 % EPS growth. The firm has "Buy" rating by Leerink Swann given on Tuesday, November 28. Piper Jaffray maintained the shares of CBAY in report on Wednesday, January 31 with "Buy" rating. Roth Capital initiated Cymabay Therapeutics, Inc. The rating was initiated by H.C. Wainwright with "Buy" on Tuesday, September 8. On Thursday, January 4 the stock rating was upgraded by Stifel Nicolaus to "Buy". (NYSE:ETM) has "Buy" rating given on Monday, November 27 by Noble Financial. (NASDAQ:CBAY) earned "Buy" rating by Piper Jaffray on Monday, July 17. Cantor Fitzgerald has "Buy" rating and $4000 target.

При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2018 Copyright.
Автоматизированное извлечение информации сайта запрещено.

Код для вставки в блог

Latest News